Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9584
+0.05786.42%
Post-market: 0.9506-0.0078-0.81%17:13 EDT
Volume:11.34M
Turnover:10.70M
Market Cap:265.58M
PE:-8.62
High:0.9630
Open:0.9000
Low:0.9000
Close:0.9006
52wk High:3.22
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.41
T/O Rate:4.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.06%
PB:10.62
PE(LYR):-46.11

Loading ...

Akebia Therapeutics Cut to Market Perform from Outperform by Leerink Partners

Dow Jones
·
Aug 08

Akebia downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Aug 07

Akebia Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Akebia Q2 FY26 Turns to Net Loss of $8.9 Million; Revenue Falls 21.44% to $49.1 Million

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Benzinga Earnings
·
Aug 06

Akebia Therapeutics Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Akebia Grants 2 New Hires Options for 61,000 Shares at $1.32 Each

Reuters
·
Aug 04

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Akebia Initiates Phase 2 Basket Trial of Complement Inhibitor Ebribafusp in Rare Kidney Diseases

Reuters
·
Aug 03

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

THOMSON REUTERS
·
Aug 03

Akebia Therapeutics Schedules Quarterly Results Release, Conference Call

Reuters
·
Jul 29

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Jul 29

Monopar Adds Ex-kalvista CCO Nicole Sweeny to Board

Reuters
·
Jul 20

Akebia Grants 125,600 Inducement Stock Options to New Hires at USD 1.14 a Share

Reuters
·
Jul 03

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Akebia Therapeutics Price Target Maintained with a $6.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 01

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)

TIPRANKS
·
Jul 01

Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis

MT Newswires Live
·
Jun 30

Akebia Therapeutics - Usrc Kidney Research Stops Voice Trial After Interim Analysis Shows Improved Safety with Vafseo

THOMSON REUTERS
·
Jun 30